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Complex focal chromosomal rearrangements in cancer genomes, also called “firestorms”,
can be scored from DNA copy number data. The complex arm-wise aberration index (CAAI)
is a score that captures DNA copy number alterations that appear as focal complex events
in tumors, and has potential prognostic value in breast cancer. This study aimed to validate
this DNA-based prognostic index in breast cancer and test for the first time its potential
prognostic value in ovarian cancer. Copy number alteration (CNA) data from 1950 breast
carcinomas (METABRIC cohort) and 508 high-grade serous ovarian carcinomas (TCGA data-
set) were analyzed. Cases were classified as CAAI positive if at least one complex focal
event was scored. Complex alterations were frequently localized on chromosome 8p
(n ¼ 159), 17q (n ¼ 176) and 11q (n ¼ 251). CAAI events on 11q were most frequent in estro-
gen receptor positive (ERþ) cases and on 17q in estrogen receptor negative (ER) cases. We
found only a modest correlation between CAAI and the overall rate of genomic instability
(GII) and number of breakpoints (r ¼ 0.27 and r ¼ 0.42, p < 0.001). Breast cancer specific sur-
vival (BCSS), overall survival (OS) and ovarian cancer progression free survival (PFS) were
used as clinical end points in Cox proportional hazard model survival analyses. CAAI pos-
itive breast cancers (43%) had higher mortality: hazard ratio (HR) of 1.94 (95%CI, 1.62e2.32)
for BCSS, and of 1.49 (95%CI, 1.30e1.71) for OS. Representations of the 70-gene and the 21-
gene predictors were compared with CAAI in multivariable models and CAAI was indepen-
dently significant with a Cox adjusted HR of 1.56 (95%CI, 1.23e1.99) for ERþ and 1.55 (95%CI,
1.11e2.18) for ER disease. None of the expression-based predictors were prognostic in the
ER subset. We found that a model including CAAI and the two expression-based prog-
nostic signatures outperformed a model including the 21-gene and 70-gene signatures
but excluding CAAI. Inclusion of CAAI in the clinical prognostication tool PREDICT signifi-
cantly improved its performance. CAAI positive ovarian cancers (52%) also had worse prog-
nosis: HRs of 1.3 (95%CI, 1.1e1.7) for PFS and 1.3 (95%CI, 1.1e1.6) for OS. This study validates
CAAI as an independent predictor of survival in both ERþ and ER breast cancer and re-
veals a significant prognostic value for CAAI in high-grade serous ovarian cancer.
ª 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Expression profiling of breast cancers has provided impor-Breast and ovarian cancer are major causes of morbidity and
death (Jemal et al., 2010). Current treatment for breast cancer
includes a combination of surgery, radiotherapy, chemo-
therapy, endocrine agents (tamoxifen or aromatase inhibitors)
in ERþ cases and trastuzumab in HER2-positive cases
(Goldhirsch et al., 2009). Although clinical outcome has
improved dramatically with modern therapy, the challenge
remains to identify patients that could be spared overtreat-
ment, since at 15 years 58% of patients are alive despite
receiving no adjuvant chemotherapy (Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG), 2005). Markers that
couldmore precisely predict better clinical outcome are there-
fore of utmost importance.tant insights into tumor biology and clinical behavior, even
though clinical implementation is not yet routine (Perou
et al., 2000; Sørlie et al., 2001, 2003). Based on the global pattern
of gene expression, five subgroups (Luminal A, Luminal B,
HER2-enriched, Basal-like and Normal-like subgroups) were
identified, with different biology and clinical course. By
combiningDNAcopynumberalterationswithgeneexpression
using integrative clusteringwe identified 10 subtypes of breast
cancer with clearly distinct genomic drivers (Curtis et al.,
2012). IC1 is a moderate-risk group composed mostly of
Luminal B tumors. IC2 is a high-risk groupdefinedby anampli-
con at 11q13/14, and composed of a mixture of Luminal A and
B. IC3 is a low-risk Luminal A group. IC4 is a CNA-devoid group
composed by a mixture of ER tumors with lymphocytic
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tifies most of the HER2 amplified tumors. IC6 is a ZNF-703
driven poor prognosis luminal group. IC7 and IC8 are
intermediate-risk Luminal A groups. IC9 is a Luminal B group
with 8q gain. Finally IC10 are the core basal-like tumors with
high genomic instability. One of our aims was to determine
how CAAI affects prognosis in these different groupings.
Gene expression-based prognostic classifiers have beenpro-
posed to risk stratify patients (Paik et al., 2004; van de Vijver
et al., 2002; van’t Veer et al., 2002), and are already used in
some clinical environments, but their implementation in prac-
tice awaits results of ongoing trials andwill always be problem-
atic given the intrinsic instability of RNA (Borgan et al., 2011).
Furthermore it remains questionable if these genomic tests
are cost effective (Hall et al., 2012), or if they improve the perfor-
mance of current prognostic tools that integrate clinical and
pathological parameters routinely used in the clinic, such as
Adjuvant! (Ravdin et al., 2001) or PREDICT (Wishart et al., 2010,
2011, 2012). PREDICT is an online tool based on population-
based cancer registry data, similar to Adjuvant!, but that in
addition incorporatesmode of detection, HER2-status and tras-
tuzumab benefit (Wishart et al., 2012, 2011, 2010).
Ovarian cancer is the fifth leading cause of cancer related
death in US women (Jemal et al., 2010). The majority of these
deaths occur in patients with advanced stage, high-grade se-
rous ovarian carcinomas (HGSOC) (Koonings et al., 1989;
Seidman et al., 2004), despite optimal cytoreduction by de-
bulking surgery and adjuvant chemotherapy (Ozols, 1997).
Major prognostic factors are age at diagnosis, performance
status, histology and residual tumor size (Winter et al., 2007,
2008). Recent studies have sought to developmolecular classi-
fications, but these do not significantly improve prognostic
performance (Cancer Genome Atlas Research Network, 2011;
Etemadmoghadam et al., 2009).
Genomic rearrangements in breast cancer have distinct pat-
terns, possibly reflecting different mechanisms of genomic
instability (Hicks et al., 2006). Analysis of somatically acquired
copy number alterations (CNA) has identified distinct types of
structural changes (e.g. whole-arm alterations and firestorms)
(Hicks et al., 2006; Russnes et al., 2010). Clustered narrow peaks
of high copy number gains characterize ‘firestorms’. We devel-
opeda score, theComplexArm-wiseAberration Index (CAAI), to
quantify such complex events (Russnes et al., 2010). In our orig-
inal reportCAAIwasshown tohave independent prognosticpo-
wer (Russnes et al., 2010), but this finding needs to be
independently validated.Herewe report such independent vali-
dation of the prognostic value of CAAI in 1950 breast carci-
nomas (Curtis et al., 2012), and show that it adds to the gene
expression-based prognostic classifiers (the 70-gene and the
21-gene signatures) (Paik et al., 2004; van de Vijver et al., 2002).
We also evaluate CAAI as a prognostic marker in 508 advanced
stage HGSOC (Cancer Genome Atlas Research Network, 2011).2. Materials and methods
2.1. Breast cancer cases
A total of 1950 breast cancer cases from theMETABRIC (Molec-
ular Taxonomy of Breast Cancer International Consortium)cohort (Curtis et al., 2012) were included in this study. Female
breast cancer cases were selected on the basis of invasive his-
tology (in-situ and benign cases were excluded, as well as
cases with unknown histology). Using an eQTL-based
approach (Lynch et al., 2012) a few cases with mismatched
DNA/RNA were identified, and excluded. This resulted in
1950 cases with gene expression, SNP-array and clinical data
available for analysis (flow chart of included samples in
Appendix A). Clinical and pathological variables were
collected from hospital reports. Estrogen receptor status by
IHC (immunohistochemistry) was available for 1921 samples
and ER status for the remaining 29 samples was scored by
the expression value of ESR1 (Lehmann et al., 2011). IHC pro-
gesterone receptor status was not available, hence expression
values for PGR were used to score PR status (Lehmann et al.,
2011). HER2 status was obtained from segmented copy num-
ber data as described in the original METABRIC report
(Curtis et al., 2012). Clinical variables are presented in
Supplementary Table 1.
2.2. Serous ovarian carcinomas
A total of 508 high-grade serous ovarian adenocarcinomas,
recruited at the time of primary surgery, were obtained from
TCGA (the Cancer Genome Atlas) (NCBI/TCGA project number
2459) (Cancer Genome Atlas Research Network, 2011). A
description of the clinical variables is presented in
Supplementary Table 5.
2.3. Bioinformatic and statistical analyses
CNA profiles were obtained from Affymetrix Genome-Wide
Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). Esti-
mation of raw copy number from arrays was performed using
the CRMAv2 method implemented in the “aroma.affymetrix”
R-package (Bengtsson et al., 2009). For the SNP-probes the
two alleleswere summarized to obtain an estimate of the total
copy number. Normalized probe intensity ratios were ob-
tained with matched normal DNA for cases where such data
was available, otherwise an average of a pool of 473 adjacent
normal tissue samples and 270 HapMap samples were used.
Raw normalized copy number estimates were segmented
into regions of constant copy number with PCF (Piecewise
Constant Fit) with the smoothing parameters kmin ¼ 5 and
gamma ¼ 200 (Nilsen et al., 2012). CAAI was then scored as
previously described (Russnes et al., 2010). The method com-
putes scores that capture complex rearrangements for each
chromosomal arm separately, based on the segmented copy
number data (Nilsen et al., 2012), and calls the tumor CAAI
positive if the score exceeds the set threshold in at least one
chromosomal arm. Gene expression data was available for
the METABRIC cases and used to derive the PAM50 subtype
classifications (Curtis et al., 2012), as well as representations
of the 21-gene (Paik et al., 2004) and 70-gene prognostic classi-
fiers (van’t Veer et al., 2002). All statistical analyses were per-
formed using R version 2.15.0 with the packages ‘copynumber’
and ‘rms’ (Gentleman et al., 2004; Harrell, 2014; Nilsen et al.,
2012). A subset of 32 samples from METABRIC was also pro-
filed with Molecular Inversion Probe (MIP) arrays, a method
for copy number profiling optimized for use with paraffin-
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marker using the breast cancer prognostic tool PREDICT
(www.predict.nhs.uk) (Wishart et al., 2012, 2011, 2010). The
predictive performance of CAAI in the ovarian cohort was
assessed by internal validation to correct for potential over-
fitting, given no adequate independent dataset for validation
was available, using the bootstrap resampling technique
(Halabi et al., 2003; Harrell, 2001). The study complies with
the Reporting Recommendations for Tumor Markers
(REMARK) (McShane et al., 2005). A detailed description of ma-
terials and methods can be found in Appendix A (Supplemen-
tary material and methods).3. Results
3.1. Breast cancer3.1.1. CAAI distribution and correlation with overall genomic
instability
A total of 835 (43%) of the 1950 breast cancer cases were CAAI
positive (Supplementary Figure 1). CAAI positivity was signif-
icantly associated with larger tumors, higher grade, negative
ER and PR (progesterone receptor), and amplification of the
HER2 gene (Supplementary Table 1). CAAI events were most
frequent on 11q in ERþ cases and 17q in ER cases. Hierarchi-
cal clustering of the CAAI positive cases based on binary
dissimilarity and Ward’s method, revealed groups dominated
by 1q, 8p, 11q or 17q complex alterations, andwith a tendency
for mutually exclusivity (Figure 1A). The proportion of CAAI
positive cases in the 1950 breast cancer cases was variable
across both the ten integrative subtypes recently described
(Curtis et al., 2012) and across the five expression-based
intrinsic subtypes (Perou et al., 2000) (Figure 1B and C).
Cancer genomes show a wide range of copy number
changes and patterns, both within and between tumor types
(Beroukhim et al., 2010). To explore how CAAI was related to
the overall instability of the genome, we calculated the frac-
tion of the genome affected by copy number change (Genomic
instability index, GII) and counted the number of DNA break-
points. In Figure 2 the results are presented and show only
modest correlation with r¼ 0.28 and r¼ 0.42 for GII and break-
points respectively (p < 0.001). CAAI positive cases can be
found in tumors with a low number of breakpoints and tu-
mors with low degree of genomic instability. This suggests
CAAI and overall genomic instability capture distinct pro-
cesses and are the result of different underlying biological
mechanisms.
3.1.2. CAAI is validated as a prognostic index
CAAI status was significantly associated with outcome, both
BCSS and OS (Figure 3). This association persisted when cases
were stratified for lymph node and ER status. Importantly, the
separation between good and poor prognosis was indepen-
dent of adjuvant systemic therapy (Supplementary Figure 2).
Results from univariable Cox regression analyses are summa-
rized in Supplementary Table 2. Positive CAAI status was
prognostic for both BCSS (HR 1.94 (95%CI, 1.62e2.32;
p < 0.001)) and OS (HR 1.49 (95%CI, 1.30e1.71; p < 0.001)).CAAI status was significantly different distributed in the
intrinsic subtypes, with CAAI positive tumorsmost frequently
found in HER2-enriched (61.8%) and Luminal B (59.9%) sub-
groups. The frequency of CAAI positive tumors in Basal-like,
Luminal A and Normal-like subgroups were 40.8%, 30.4%
and 26.3% respectively. CAAI status was associated with
higher mortality within each of the intrinsic subtypes, except
for Luminal B tumors (Supplementary Figure 3). CAAI was also
prognostic in IC4, IC7 and borderline significant in IC10
(Supplementary Figure 4). The HER2-enriched Pam50 sub-
group overlap with, but is not equal to the clinical HER2 ampli-
fied group. In IC5 all tumors haveHER2 gene amplification, but
not all HER2þ tumors belong to IC5. CAAI was prognostic in
HER2 amplified tumors (by SNP-array) and in the Pam50
HER2-enriched group, but not in IC5 subgroup
(Supplementary Figure 5). A total of 64.4% of the HER2 ampli-
fied tumors by SNP-array were CAAI positive. Interestingly
only 139 of the 279 CAAI positive HER2 amplified tumors
(49.8%) had a complex alteration affecting chromosome 17q,
the remainder had complex events elsewhere in the genome,
most frequently affecting 11q and 8p. This shows that not all
HER2 amplified cases have a complex structural alteration
affecting the HER2 amplicon, but rather a more simple
amplification.
The CAAI score is a continuous numeric value (range
0.0e22.4 in the 1950 breast cancer cases). To classify samples
as CAAI positive and negative (dichotomous variable) we used
the same threshold value of 0.5 as in our original report
(Russnes et al., 2010). Using a log2 transformation of the
continuous CAAI as a variable in a Cox regression model
showed an HR of 1.46 (95%CI, 1.33e1.61; p< 0.001). This signif-
icant association between the continuous numeric CAAI score
and outcome illustrates that results are not dependent on the
chosen threshold, but since the present study is an indepen-
dent validation of the prognostic value of CAAI, we used the
dichotomized variable for all the multivariable models (see
below).
3.1.3. Multivariable survival analysis
Results from multivariable Cox regression models for BCSS
are presented in Table 1 (and for OS are shown in
Supplementary Table 3). When comparing ERþ and ER tu-
mors the proportional hazard varies over time (Blows et al.,
2010). We therefore fitted separate Cox models for ERþ and
ER cases. In the 1412 ERþ cases CAAI status, tumor size,
lymph node status, age, histologic type (ILC vs. IDC) and the
surrogate 21-gene predictor were significant after adjustment
for covariates. Positive CAAI had an HR of 1.56 (95%CI,
1.23e1.99; p < 0.001). A total of 421 ER cases were available
for multivariable analysis, and only axillary lymph node sta-
tus, histological type and CAAI status remained significant
(HR 1.55 (95%CI, 1.11e2.18; p ¼ 0.011)). Neither of the two
expression-based signatures (that is surrogates to resemble
Mamma Print and OncoTypeDX, see below), was found to be
significant in ER disease.
3.1.4. CAAI provides additional stratification to gene
expression classifiers
The prognostic value of the two gene expression prognostic
classifiers (Paik et al., 2004; van de Vijver et al., 2002) was
AB C
Figure 1 e Distribution of complex events in breast cancerHierarchical clustering of the CAAI positive cases is shown in panel A, with CAAI positive
events in blue and negative in gray. The distribution of CAAI positive cases in molecular subtypes of breast cancer is shown in B (integrative
cluster subtypes) and C (PAM50 subtypes).
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and 70-gene signatures as described in supplementary infor-
mation and presented in Supplementary Figure 6. CAAI status
was able to further stratify each of the gene expression risk
groups (Supplementary Figure 7). CAAI provides added prog-
nostic information in all subsets, with the strongest effect in
the high-risk groups. To evaluate the added predictive ability
of a new biomarker, such as CAAI, is a complex task, as statis-
tical significance is not always the same as clinical signifi-
cance (Pencina et al., 2008). For this reason, we comparedthe performance of prognostic models in the complete data-
set, and in ERþ and ER disease separately, using three
different statistical measures proposed in the literature: the
likelihood ratio test, the C-index (Harrell et al., 1996), a mea-
sure of the concordance between predicted and observed sur-
vival times, and finally U-statistics based on net classification
improvements (Pencina et al., 2011), to formally test the signif-
icance of the increase in the C-index. The results of these an-
alyses, presented in Supplementary Table 4, confirm that a
model including CAAI and the two expression-based
Figure 2 e CAAI and overall Genomic Instability Scatter plot of maximum CAAI score and Genomic Instability Index on the actual (A) and a
logarithmic (B) scale, colored by CAAI status. Boxplot of GII in CAAI negative and positive cases, colored by number of breakpoints (C). Scatter
plot of maximum CAAI score and the number of DNA breakpoints (D), and on a logarithmic (E) scale, colored by CAAI status. Boxplot of
number of DNA breakpoints in CAAI negative and positive cases, colored by GII (F).
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gene and 70-gene signatures but excluding CAAI.
3.2. Ovarian cancer
In HGSOC CAAI positivity was detected in 262 of the 508 (52%)
available cases. The distribution of clinical variables in the
data set is shown in Supplementary Table 5. The CAAI scores
were generally higher in the ovarian cohort than in breast can-
cer. Univariable Cox regression of the continuous CAAI-score
(log2 transformed) showed a significant HR of 1.3 (95%CI,
1.2e1.5; p < 0.01). We chose a threshold of 1.0 for the subse-
quent analyses to reflect the more rearranged genome of
ovarian cancer. KaplaneMeier plots illustrate the prognostic
impact of CAAI status on progression free survival (PFS)
(p¼ 0.013) and OS (p< 0.001) (Figure 4). Univariable Cox regres-
sion models for all clinical variables are presented in
Supplementary Table 6. CAAI positive cases had an increased
risk of progression with HR 1.3 (95%CI, 1.1e1.6; p ¼ 0.01)
and for death of any cause with HR 1.4 (95%CI, 1.2e1.7;
p  0.01).
The results frommultivariable Cox regression analyses are
presented in Table 2. Age at diagnosis did notmeet the propor-
tional hazards (PH) assumption and the model was stratified
by a categorical representation of age (60 vs. >60). Positive
CAAI increased risk of relapse, independent of other covari-
ates with a HR of 1.3 (95%CI, 1.1e1.7; p ¼ 0.01). CAAI was
together with histological grade a predictor of OS, with HR of
1.3 (95%CI, 1.1e1.6; p< 0.01). Since no adequate external/inde-
pendent dataset was available, an internal validation of themultivariable models was performed using bootstrapping to
correct for potential over-fitting (Halabi et al., 2003; Harrell,
2001). Supplementary table 7 shows the result of the valida-
tion using several indexes (details in supplementarymaterial).
The amount of over-fitting in the models was modest, as re-
flected by the estimated optimism. Supplementary Figure 8
shows the predictions from the models at 1 and 2 years of
follow up compared with the actual survival probability (cali-
bration accuracy). The agreement between the observed and
predicted survival was highly concordant; mean optimism
0.002 for PFS at both time points and 0.003 and 0.002 for OS
at 1 and 2 years of observation respectively.3.3. Possible clinical utility of CAAI in breast cancer
3.3.1. CAAI in FFPE tumor material
Most aCGH-based analyses rely on availability of fresh frozen
tumor material. Molecular inversion probe (MIP) arrays have
been developed for analysis of FFPE material and this could
facilitate clinical implementation of CAAI analysis. We there-
fore compared 32 samples hybridized to both Affymetrix SNP
6.0 and MIP platforms. Supplementary Figure 9 shows the
good correlation between CAAI scores obtained with the two
platforms in matched fresh-frozen and paraffin-embedded
samples. Using an optimized threshold for the MIP data the
agreement between methods was substantial: Cohen’s Kappa
value of 0.75. These preliminary results suggest that CAAI
scoring could be implemented using formalin fixed paraffin-
embedded tumor material.
AC D
E F
B
Figure 3 e KaplaneMeier estimates of outcome in breast cancer In A and B survival estimates for CAAI positive and negative cases are shown for
breast cancer specific survival (BCSS) and overall survival (OS) respectively. Outcome for lymph node negative and lymph node positive cases are
shown in C and D. E and F shows survival estimates for ERD and ERL cases.
Table 1 eMultivariable Cox regression model with breast cancer specific survival as outcome variable.
Variable ER positive cases (n ¼ 1412) ER negative cases (n ¼ 421)
HR 95% CI p-value HR 95% CI p-value
Lower Upper Lower Upper
Any genomic complex events
CAAI pos vs. neg 1.56 1.23 1.99 <0.001 1.55 1.11 2.18 0.011
Histological grade
Categories as ordinal 1.13 0.92 1.38 0.247 0.77 0.49 1.23 0.281
Tumor size
pT2 vs. pT1 1.50 1.17 1.93 0.001 1.36 0.94 1.96 0.105
pT3 vs. pT1 3.62 2.30 5.70 <0.001 1.08 0.55 2.11 0.819
Axillary lymph node status
Positive vs. negative 2.27 1.78 2.88 <0.001 2.07 1.37 3.14 0.001
HER2 status (from arrays)
Positive vs. negative 0.99 0.75 1.31 0.941 0.99 0.70 1.40 0.967
Progesterone receptor status
Positive vs. negative 1.05 0.81 1.35 0.731 0.86 0.44 1.66 0.646
Age at diagnosis
Continous variable 1.01 1.00 1.02 0.024 0.99 0.97 1.00 0.167
Histological type
ILC vs. IDC 1.73 1.15 2.60 0.009 1.25 0.49 3.14 0.641
Other invasive vs. IDC 1.05 0.68 1.60 0.838 0.36 0.15 0.86 0.021
70-gene classifier
Poor vs. good prognosis 1.25 0.95 1.64 0.110 1.00 0.54 1.86 0.999
21-gene classifier
Moderate vs. good prognosis 1.23 0.91 1.68 0.179 1.21 0.35 4.23 0.763
Poor vs. good prognosis 2.35 1.64 3.36 <0.001 1.14 0.35 3.69 0.824
Separate models for ER positive and negative cases. Significant p-values (<0.05) in bold. Both models were stratified for site of inclusion.
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(Wishart et al., 2012, 2011, 2010)
CAAI as a prognostic marker was added to the prognostic
model PREDICT (www.predict.nhs.uk) (Wishart et al., 2012,
2011, 2010), which is based on a Cox proportional hazard
model. PREDICT was developed using a case-cohort of breast
cancer cases of unknown CAAI status and so the underlying,
baseline hazard is representative of cases of average CAAI sta-
tus. The CAAI hazard ratio estimate is for CAAI positive
compared to CAAI negative cases, and so these were rescaled
to give an average hazard ratio of unity using an estimated
prevalence of CAAI positivity of 40 percent. We thenA B
Figure 4 e KaplaneMeier estimates of outcome in ovarian cancer Survival estim
survival (A) and overall survival (B).compared the performance of PREDICT with and without the
addition of CAAI in predicting breast cancer specific mortality
at five years after diagnosis using calibration, discrimination
and reclassification as measures of model performance.
Model calibration is a comparison of the predicted mortality
estimates from each model with the observed mortality.
Model discrimination was evaluated by calculating the area
under the receiver-operator-characteristic curve (AUC) calcu-
lated for 5-years breast cancer specific mortality. This is a
measure of how well the models identify those patients with
poorer survival. The AUC is the probability that the predicted
mortality from a randomly selected patient who died will beates for CAAI positive vs. CAAI negative cases with progression free
Table 2 e Multivariable Cox regression models in ovarian cancer.
Variable Progression free survival Overall survival
HR 95% Confidence
interval
p-value HR 95% Confidence
interval
p-value
Lower Upper Lower Upper
Any complex genomic events (CAAI)
Positive vs. negative 1.3 1.1 1.6 0.01 1.8 1.3 2.4 <0.01
FIGO stage
Stage IV vs. stage III 1.2 0.9 1.6 0.13 1.2 0.9 1.8 0.26
Histological grade
Grade 3 vs. Grade 2 1.4 1.0 2.0 0.05 1.2 0.8 1.9 0.38
Residual disease
Suboptimal (>10 mm residual tumor)
vs. optimal (<10 mm)
0.9 0.7 1.2 0.49 1.1 0.8 1.5 0.69
The model was stratified for age. Significant p-values (<0.05) in bold.
n ¼ 368 (38 excluded due to missing data).
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survivor. Reclassification is the extent to which a new model
classified individuals into specified risk groups. PREDICT is
used in a clinical setting to identify patients most likely to
benefit from adjuvant chemotherapy. The Cambridge Breast
Unit multi-disciplinary team uses the estimated absolute
benefit of chemotherapy at ten years to define three patient
groups: those with a predicted absolute benefit of less than 3
percent in whom chemotherapy is not recommended, those
with a predicted absolute benefit of 3e5 percent in whom
the balance of risks and benefits are discussed with the pa-
tients, and those with an absolute benefit of greater than 5
percent for whom chemotherapy is generally recommended.
The absolute benefit is approximately proportional to the ab-
solute risk. We therefore classified the 1950 cases from the
breast cancer cohort into three groups based on thresholds
for estimated absolute benefit at five years of 1.5 percent
and 2.5 percent.
We tested whether the addition of CAAI to the PREDICT
prognostic model (modified PREDICT) could improve both
model calibration andmodel discrimination in the breast can-
cer cohort of 1950 cases. In the first five years following diag-
nosis there were 299 breast cancer deaths, this compared
with 276 predicted using PREDICT and 283 using the modified
PREDICT. The improved calibrationwas seen for both ERþ and
ER disease. The discrimination for the modified PREDICT
(AUC ¼ 0.775) was significantly better (p ¼ 0.005) than for PRE-
DICT (AUC ¼ 0.764). PREDICT is typically used in the clinical
setting to estimate the absolute benefit of adjuvant chemo-
therapy. Supplementary Table 8 shows the stratification of
the breast cancer cases into the three absolute benefit groups:
less than 1.5% (when chemotherapy is not recommended),
1.5e2.5% (when chemotherapy is discussed), and greater
than 2.5% (when chemotherapy is recommended). 1706 pa-
tients remained in the same group under both models. Of
the 244 cases that changed risk groups using modified PRE-
DICT, 134moved into a groupwith a smaller predicted benefit,
potentially sparing them chemotherapy, and 110 moved to a
higher risk group, potentially resulting in them receiving the
added benefit of chemotherapy.4. Discussion
In this study we validate CAAI, a measure of complex struc-
tural alterations in cancer genomes, as an independent prog-
nostic biomarker in breast cancer, and reveal its significant
prognostic value also in ovarian cancer. The size of the META-
BRIC breast cancer cohort (1950 cases) and the comprehensive
clinical data available enabled stratification by relevant sub-
groups, and showed that CAAI is an independent predictor
of outcome in both ER and ERþ disease. The prognostic effect
was found in both chemotherapy na€ıve and chemotherapy
treated patients. The novel finding of the prognostic effect of
complex focal DNA copy number change in ovarian cancer,
captured by CAAI, is interesting as the method was developed
for breast cancer. Since it has proven challenging to identify
prognostic markers in ovarian cancer, the modest effect of
CAAI needs independent validation.
Analyses of copy number data rely on a robust smoothing
of the raw data into estimates of the underlying copy number
state. Different algorithms for such analysis exist and the in-
dividual methods have different settings to control the sensi-
tivity and the specificity of calls. In this analysis PCF was used
after normalization of CEL files, to make it as similar to our
previous results as possible. This was essential since our
aimwas to validate the prognostic value of CAAI in breast can-
cer. Threshold parameters were kept constant for the valida-
tion in breast cancer, but were adjusted in ovarian cancer
due to the more aneuploid background of these genomes. As
for most novel tests, thresholds for calling of positives over
negatives could be optimized and improved. The prognostic
effect of CAAI used as a continuous score, both in breast and
ovarian cancer, was clear, indicating that results are not
dependent on the thresholds used.
Becausewe hadmatched gene expression profiling data for
all the 1950 breast cancers cases we could use this data to
implement surrogate indices for the 21-gene and 70-gene
prognostic gene expression classifiers that are currently being
validated in two large clinical trials; MINDACT (Cardoso et al.,
2007, 2008; Rutgers et al., 2011) (ClinicalTrials.gov nr.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 1 5e1 2 7124NCT00433589) and TAILORx (Sparano, 2006; Sparano and Paik,
2008) (ClinicalTrials.gov nr. NCT00310180). We could therefore
show, using a multivariable Cox regression model, that the
prognostic value of CAAI was independent of these gene
expression classifiers. Moreover we could also robustly eval-
uate, using three statistical measures, the added value of
CAAI in a model that also included the 21 and 70 gene expres-
sion signatures. These results indicate that even if MINDACT
or TAILORx demonstrate the clinical utility of gene expression
classifiers, CAAI would add further prognostic information
and therefore have clinical impact.
CAAI was designed to capture focal complex copy number
aberrations. Our comparison with overall genome instability,
measured by GII and number of breakpoints, shows that
CAAI is only modestly correlated with these. This finding sug-
gests that there are distinct biological processes underlying
these distinct patterns. The CAAI index captures localized re-
gions of copy number change, but in a genomic profile that is
characterized by extensive structural variation, the indexmay
call other patterns as well. On the other hand the method is
sensitive to score genomes that overall have few changes,
but with distinct localized clustered events. A total of 35.6%
(154/433) of the HER2 amplified tumors (by SNP-array) are
CAAI negative, showing that a single amplicon containing a
known driver gene does not necessarily result in a sample
being called CAAI positive. Luminal B and the HER2-enriched
tumors are more often CAAI positive than others. Intriguingly
CAAIwas not significantly associatedwith survival in Luminal
B tumors. We noted that curves in the KM-plot joined towards
the end of the 15 years observation time, probably
reflecting non-breast cancer mortality with very long follow
up time.
The exact mechanism by which firestorms affect clinical
outcome is not known. Firestorms are thought to arise from
breakage-fusion-bridge cycles, either associated with fragile
sites, or as result of recombination at palindromic sites at
shortened telomeres (Hicks et al., 2006), resulting in focal am-
plifications, frequently at sites of known oncogenes such as
ERBB2 or CCND1. These genomic events could lead not only
to increased tumor aggressiveness (proliferation, invasive-
ness and metastasis) but also underpin clonal evolution as a
driver of drug resistance (Aparicio and Caldas, 2013). All of
these features would combine to portend worse outcome for
CAAI positive breast and ovarian cancers.
The potential clinical utility of CAAI was demonstrated in
breast cancer, showing it could be implemented without
requiring fresh frozen tumor material, and improving calibra-
tion and discrimination of the clinically used PREDICT prog-
nostication tool by the addition of CAAI. A test based on
DNA extracted from formalin fixed paraffin-embedded tissue
blocks, rather than RNA from fresh frozen tumor material,
would significantly facilitate implementation in routine diag-
nostic labs.Author contributions
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